Aurobindo Pharma Q2 Review - Steady Quarter Amid Significant Drag In Anti-Retrovirals: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..ICICI Direct Report.Aurobindo Pharma Ltd.'s revenues de-grew 2.1% YoY to Rs 5941.9 crore (our estimate: Rs 6117.4 crore) amid a 6.9% YoY growth in U.S. business to Rs 2967.6 crore (our estimate Rs 2888 crore) and 9.7% YoY growth in Europe formulations to Rs 1662 crore (our estimate: Rs 1597.9 crore). Rest of world markets de-grew 13.5% YoY to Rs 386.3 crore (our estimate Rs 401.9 crore). On the other hand, Aurobindo Pharma's anti-retroviral segment de-grew 71.2% YoY to Rs 145 crore (our estimate Rs 351.9 crore) while active pharma ingredient segment de-grew 5.8% YoY to Rs 780.6 crore (our estimate Rs 829 crore).[Note: Revenue from Natrol excluded for ease of comparison]. Ebitda margins were down 213 basis points YoY at 20% (our estimate: 19.7%) due to cost pressure on some of the key raw materials as well as higher logistic costs. .Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Aurobindo Pharma Q2 Review - Steady Quarter Amid Significant Drag In Anti-Retrovirals: ICICI Direct

Aurobindo Pharma Q2 Review - Steady Quarter Amid Significant Drag In Anti-Retrovirals: ICICI Direct

Choose a plan